Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 1.07% 141.50 140.00 143.00 144.50 138.50 140.00 246,235 15:58:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 6.7 -0.6 -1.5 - 44

Cambridge Cognition Share Discussion Threads

Showing 476 to 500 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
An investor in COG has dedicated a pledge to charity if the share price reaches £1.45 this year for a £200 donation to be made to a small deserving charity. I was only dedicated this week and looks like it will be hit this week at the current rate of growth in share price. Hundreds of investors are doing the same Https:// You can choose any company and any charity or simply match another investor and their pledge. I am hoping to get to £100k for lots of smaller deserving charities mainly but all donations much appreciated. Lets hope the markets stay positive and investors are generous.
I added earlier. Was hard to get any, but already in profit on them which is nice....
Indeed, thanks for that perceptive analysis 40 Fathoms
40 Fathoms - many thanks much appreciated
I think there are a number of possible reasons. 1) It is already clear they will blow away the @8.5 million revenue figure they have put out for 2021 and we are only 1/3 of the way through the year. 2) Following on from the point above this would suggest that they will also be meaningfully profitable this year. My working assumption is they will top GBP 1.25 million in PBT this year and depending on how the contracts build that could well top GBP 3.5 next year. Even at 125p per share that puts them on a P/E of 12 x next year and probably single digit for 2023. 3) On 7th April Goldman Sachs did a whole day of talks and panel discussions devoted to digital medicine and with particular focus on how digital clinical trials are now going mainstream. I understand it was very well attended. 4) With the FDA PDUFA date on ADUCANUMAB coming into view (7th June) people maybe positioning for a positive outcome. A positive result will be transformational for COG. It will open a large and near term market for delivering cognitive tests as a triage tool for potential AD patients. Think millions of tests a year being given at (pick your price) US$ 1.00, US$ 2.50, US$ 5 per test. That millions of tests per year will increase to tens of millions in the next decade. It is only COG and Cogstate that are in a position to serve this market. As a reminder Cogstate have done a 10 year deal with Eisai that will pay them a minimum of US$ 45 million over that period. Cogstate are very keen to emphasise that this is a minimum number and they expect very substantial upside. 5) As you suggest someone could well be building a stake, though I would argue with Nigel Wray and one or two other large PIs stakes anyone could well struggle to get to the 75% threshold required under a scheme of arrangement. 6) There is almost no 'traditional" institutional ownership of the stock. Maybe it is starting to gain some attention from the small cap insto crowd.
40 fathoms
Anyone thought of reasons for the sharp rise in share price this week? It has crossed my mind someone might be building a stake for a possible bid!!
Seems like covid is now responsible for every medical condition to keep the narrative going. Anyhow topped up on these - great prospects
1ml UK now suffering long covid conditions, the problem is being able to treat all of these different conditions, dementia,CFS,ME, etc bringing on exaggerated symptoms as the tragic recent case of CEO Kent Taylor suffering tinnitus DVLA have now a massive backlog of dementia patients at various stages cognitive impairment, awaiting driving licence renewal, in turn causing vehicle insurance problems,
Something of a remarkable day! mdchand - yes that is good news. I've only recently invested here - seemed well run, with a strong product, and in an area I felt would grow. A bit of luck really that I invested when I did. My holding is for the long term, so sort of irrelevant what the share price does in the short term - a pleasing confirmation of a decent stock choice though it may be.
Interested to note that this win was with a new Pharmaceutical Company - which helped ease a concern of mine - ie COG being overly reliant on 1/2 major Pharmas for business. If you look up leading Pharmas in the CNS space its the likes of Biogen / Pfizer / Novartis / J&J. I'm not saying it is ANY of these, but it could be.
Yes. All looks pretty promising for the long term.
Another very nice contract win. At home, unsupervised, more frequent cognitive testing that is the future for many clinical trials. COG and Cogstate have this space pretty much to themselves.
40 fathoms
Another really nice chunky contract win !
40 fathoms
Just to mention that Cambridge Cognition will be one of ten companies featured in the March results round up in the MelloMonday show tonight. It will be a really packed five hour show but here are the timings.... Programme for the evening 5.00 pm Introduction to our Mello Roadshow 5.05 pm Alun @MrContrarian reviews the Mello BASH companies 5.10 pm Company presentation by Judges Scientific 5.40 pm How to join corporate fundraisings with Primary Bid 6.00 pm Company presentation by Filta Group 6.30 pm Leon Boros interviews Peter Harrison from Bioventix 7.00 pm Company presentation by Digital Box 7.30 pm A March results round up with Paul Scott, Gordon @glasshalfull & Alan Charlton 8.00 pm Company presentation by Get Busy 8.30 pm New IPO presentation by Parsley Box introduced by James Deal, Primary Bid 8.50 pm Mello BASH with Alan Charlton, Alex Schlich, Richard Crow (@RebelHQ) and Kevin Taylor If you have not been before the webpage is here Https:// Do use this code for a half price ticket MMTADVFN50
Enegeticbacker. You are spot on, if you go back and read through the annual reports they have a tonne of stuff they have suspended to focus on getting to profitability. Also at some point there is a healthcare deal to be done and Cogstate (the only real competitor)did a deal with Eisai for a minimum of US$ 45 million over 10 years. I think that sets the benchmark for what a deal may look like.
40 fathoms
Investor's Champion comments: The current c£25m valuation (share price 80p - previously 74p), equivalent to only 3.7x historic sales, does not appear to reflect the considerable amount of intellectual property it has accumulated over the past 30 years, supported by thousands of peer-reviewed publications.
Cracking results and outlook. And as they predicted profitable in the 4th quarter. Will only raise cash for bolt on acquisitions. There is a very long runway in this name. Will get some of the granular details at the presentation later today. Well done to the management team.
40 fathoms
In case you missed our webinar with Cambridge Cognition the recording and stockopedia report can be found here: hTTps:// To access the recording, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps:// Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the recording (and recordings/reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://
I hosted the sharesoc webinar this evening and found it really interesting. Recommend anyone looking at this company check it out at the ShareSoc website
donald pond
We are hosting a webinar with Cambridge Cognition which may be of interest for current shareholders or potential investors: hTTps:// Matthew Stork – Chief Executive Officer will be presenting.
The spread on this share is abnormally wide....must have put lot of people off!
Investor's Champion published today an in-depth analysis of COG including background, competitors, financials, valuation and more.
It will not be quiet for too long. The FDA have just taken the unusual step of extending the PDUFA date for the approval of Aducanumab by 3 months after requesting more analysis and data. This is not something you would do, especially after the ADCOM feedback, if you intended to issue a complete response letter. With Aducanumab approved and with promising results from Lilly, Shanghai Green Valley and Grifols on the horizon one way or another we are going to get a diseases modifying drug and when we do Cognitive testing is going to be become ubiquitous for the over 60s.
40 fathoms
Shh... just bumping the thread up my list. It's lovely and quiet.
Very nice trading update and it looks like they were indeed profitable in Q4, as they had previously forecast. We should be looking at a maiden year of profitability in 2021. Particularly pleased to see the order backlog increase so meaningfully, long may it continue.
40 fathoms
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
ADVFN Advertorial
Your Recent History
Cambridge ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 12:41:32